.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,814,643

« Back to Dashboard

Details for Patent: 5,814,643

Title: Sulfonamide fibrinogen receptor antagonists
Abstract:A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
Inventor(s): Duggan; Mark E. (Narberth, PA), Egbertson; Melissa S. (Ambler, PA), Halczenko; Wasyl (Hatfield, PA), Hartman; George D. (Lansdale, PA), Laswell; William L. (Perkasie, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Filing Date:May 22, 1997
Application Number:08/861,545
Claims:1. A method for inhibiting platelet aggregation in a mammal resulting from interaction of platelets with artificial surfaces, which comprises treating the mammal with a pharmacologically effective amount of a compound of the structural formula ##STR209## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is

aryl,

C.sub.1-10 alkyl, or

C.sub.4-10 aralkyl,

wherein aryl is phenyl, pypridyl, thienyl, tetrazole or oxazole;

R.sup.5 is ##STR210## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR211## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;

Z is ##STR212## p is zero or one; and m is an integer from two to six.

2. A method of claim 1, wherein the compound has the structural formula ##STR213## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is

aryl,

C.sub.1-10 alkyl, or

C.sub.4-10 aralkyl,

wherein aryl is phenyl, pyridyl, thiophenyl, tetrazole, or oxazole;

R.sup.5 is ##STR214## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR215## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;

Z is O;

p is zero or one; and

m is an integer from two to six.

3. A method of claim 2, wherein the compound is ##STR216## and pharmaceutically acceptable salts thereof.

4. A method of claim 2, wherein the compound is ##STR217## and pharmaceutically acceptable salts thereof.

5. A method of claim 2, wherein the compound is ##STR218## and pharmaceutically acceptable salts thereof.

6. The method of claim 3, wherein the salt is ##STR219##

7. A method for inhibiting platelet aggregation in a mammal resulting from interaction of platelets with artificial surfaces, which comprises treating the artificial surface with a pharmacologically effective amount of a compound of the structural formula ##STR220## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is

aryl,

C.sub.1-10 alkyl, or

C.sub.4-10 aralkyl,

wherein aryl is phenyl, pyridyl, thienyl, tetrazole or oxazole;

R.sup.5 is ##STR221## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR222## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;

Z is ##STR223## p is zero or one; and m is an integer from two to six.

8. A method of claim 7, wherein the compound has the structural formula ##STR224## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is

aryl,

C.sub.1-10 alkyl, or

C.sub.4-10 aralkyl,

wherein aryl is phenyl, pyridyl, thiophenyl, tetrazole, or oxazole;

R.sup.5 is ##STR225## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR226## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;

Z is O;

p is zero or one; and

m is an integer from two to six.

9. A method of claim 8, wherein the compound is ##STR227## and pharmaceutically acceptable salts thereof.

10. A method of claim 8, wherein the compound is ##STR228## and pharmaceutically acceptable salts thereof.

11. A method of claim 8, wherein the compound is ##STR229## and pharmaceutically acceptable salts thereof.

12. The method of claim 1, wherein the salt is ##STR230##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc